Deep Intelligence Across Industries

Company Headquarters: Warsaw, Indiana, (US) Founded: 1927 Workforce: 19,000+ Company Working: Zimmer develops, produces, and markets musculoskeletal healthcare products. It is a leading brand in providing customized joint and bone healthcare solutions. It offers products related to orthopedics, healthcare, medical instruments, medical technology, surgical instruments, medical supplies, medical devices, innovation, and signature solutions. The company is present in all major markets and holds significant market share in the global tissue engineering market.

Company Headquarters: Tokyo, Japan Founded: 1939 Workforce: ~10,476 Company Working: Showa Denko KK is a chemical company that engages in the manufacturing and marketing of a wide range of petrochemicals, chemicals, electronics, inorganic chemicals, aluminum, and other products. The company, along with its affiliates and subsidiaries, operates in North America, Europe, and Asia. It provides products and services that are useful and exceed customer expectation.

Company Headquarters: San Diego, California, US Founded: 2011 Workforce: ~214 Company Working: Retrophin, Inc., is a biopharmaceutical company that develops and delivers therapies for people with rare diseases. It operates in different therapeutic areas such as fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), and other life-threatening neurological disorders. The company focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases.

Company Headquarters: Michigan, US Founded: 1941 Workforce: ~51,000 Company Working: Stryker is engaged in developing, manufacturing, and marketing specialty surgical and medical products. Its products include implants, biologics, surgical, neurologic, ear, throat, interventional pain equipment, endoscopic, surgical navigation, communications, and digital imaging systems. The company also offers products for patient handling and emergency medical equipment. It operates through three major segments: medical & surgical equipment (MedSurg), orthopedics, and neurotechnology & spine. Stryker has been focused on providing automation solutions in its product portfolio. It has a presence in over 75 countries across the globe.

Company Headquarters: New Jersey, US Founded: 1887 Workforce: 155,800 Company Working: Johnson & Johnson Services, Inc. (J&J Services) manufactures medical devices for various specialties such as orthopedics, cardiovascular diseases, and many others. J&J Services has acquired and merged with various other companies to expand its portfolio of endoscopic devices, pharmaceutical, and consumer health products. The company operates through its various subsidiary Janssen Pharmaceutica, Neutrogena, DePuy Synthes Companies, Ethicon Inc., Janssen-Cilag, Actelion, LifeScan, Inc., Johnson & Johnson Vision Care, Inc., and others. Under its Johnson & Johnson Surgical Vision business, the company offers different eye care products which include contact and intraocular lenses, under the ACUVUE brand. Additionally, in 2017, the Johnson & Johnson Surgical Vision business acquired Abbott Medical Optics Inc., and also invested in eye health by expanding into cataract surgery, laser refractive surgery (LASIK) and consumer eye health.

Company Headquarters: New Jersey, US Founded: 1989 Workforce: ~4,500 Company Working: Integra LifeSciences Holdings Corporation (Integra) is a world leader in medical technology. It offers innovative solutions for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive & general surgery. Integra offers a broad portfolio of brands that include AmnioExcel, Bactiseal, Cadence, Certas, Codman, CUSA, DuraGen, DuraSeal, ICP Express, Integra, MediHoney, MicroFrance, PriMatrix, Salto Talaris, SurgiMend, TCC-EZ, Titan, and VersaTru. It sells its products through two business segments, namely, Codman specialty surgical and orthopedics and tissue technologies. It recently acquired one of the leading players of the global amniotic membrane market, Derma Sciences Inc. (US), a tissue regeneration company. Integra provides its innovative healthcare solutions in over 130 countries through more than 50 offices and worldwide distribution networks.

Company Headquarters: New Jersey, US Founded: 2014 Workforce: ~500 Company Working: Legend Biotech is a multinational biopharmaceutical company. The company has three core cell therapy platforms—CAR-T) T-cell receptor T-cell therapy (TCR-T), and allogeneic cell therapy. The company has been developing a strong pipeline of CAR-T products to treat solid and liquid tumors. Legend Biotech is utilizing the extensive cell therapy experience of its leaders and R & D staff, global clinical partners, and expanding research facilities. It is doing so to utilize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors, infectious diseases, and autoimmune diseases

Company Headquarters: Washington, US Founded: 2013 Workforce: ~500 (2016) Company Working: Juno Therapeutics is a part of Celgene Corporation. It is a biopharmaceutical company formed through the collaboration of Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company is into the development of cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno Therapeutics is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. The company has its offices in the US and Germany. The company has its manufacturing plant in Washington, US.

Company Headquarters: France, Paris Founded: 1999 Workforce: ~161 Company Working: Cellectis is a clinical stage biotechnological company involved in the development of immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company operates through two segments—Therapeutics and Plants. Cellectis is currently developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL), UCART22 to treat ALL and non-Hodgkin lymphoma (NHL), ALLO-501 for treating relapsed/refractory NHL, and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm, among others